DO WE STICK TO INTERNATIONAL GUIDELINES WHEN TREATING EARLY STAGE HODGKIN LYMPHOMA?Carolina Oliver, Pablo Muxí, Ana Inés Landoni et al.|Hematological Oncology|2021Cited by 0
689 | HOW TO OPTIMIZE THE USE OF HIGH‐COST THERAPIES IN DLBCL: A COLLABORATIVE OBSERVATIONAL STUDY BY THE URUGUAYAN LYMPHOMA GROUPVictoria Irigoín, Ana Inés Landoni, Carolina Oliver et al.|Hematological Oncology|2025Cited by 0